Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 28;12:662782. doi: 10.3389/fimmu.2021.662782

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Radke, Li, Hernandez, El Bannoudi, Kosakovsky Pond, Shopsin, Lopez, Fenyö and Silverman

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Serum reactivity to Leukocidin S, SpA_KKAA and Spike protein in patients with Skin and Soft Tissue Infections (SSTI) and controls. (A) Serum binding reactivity measured as OD 450nm to Leukocidin S (LukS) from Staphylococcus aureus by individuals with skin and soft tissue infections (SSTI) at 1:200, 1:1000, 1:5000 and 1:25,000 serum dilutions and mAb controls at 10, 2, 0.4 and 0.08 µg/mL. (B) Binding reactivity to LukS by control serum and mAb controls. (C) Binding reactivity to SpA_KKAA by SSTI sera and mAb controls. (D) Binding reactivity to SpA_KKAA by control serum and mAb controls. (E) Binding reactivity to Spike protein from SARS-CoV-2 by SSTI sera and mAb controls. (F) Binding reactivity to Spike protein by control serum and mAb controls.